Want to see TSE:GREY full AI Analyst Report?
Top Page
Grey Matters Health
(GREY)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.53
▲(18.67% Upside)
Action:Reiterated
Date:07/03/26
The score is held down primarily by very weak financial performance (no revenue, ongoing losses, and negative free cash flow). Technicals are only neutral, with the stock still below its 200-day average and MACD negative, offering limited momentum support. Valuation provides little support given a negative P/E and no dividend yield data.
Positive Factors
Debt-free balance sheet
The absence of debt limits interest obligations and reduces balance-sheet risk while the company remains loss-making. This provides greater financial flexibility than a leveraged structure, although preserving that advantage will depend on controlling cash use and eventually building sustainable operations.
Negative Factors
No demonstrated revenue base
Zero reported revenue means the company has not yet demonstrated commercial demand or a repeatable monetization engine for its clinically oriented VR products. Without a revenue base, future growth, margin potential, and the ability to fund operations internally remain unproven over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of debt limits interest obligations and reduces balance-sheet risk while the company remains loss-making. This provides greater financial flexibility than a leveraged structure, although preserving that advantage will depend on controlling cash use and eventually building sustainable operations.
Read all positive factors
Grey Matters Health (GREY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.91M
Dividend YieldN/A
Average Volume (3M)11.43K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue GrowthN/A
EPS Growth17.84%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.62
Shares Outstanding8,923,237
10 Day Avg. Volume8,117
30 Day Avg. Volume11,432
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.02
Revenue Forecast (FY)C$45.78M
Grey Matters Health Business Overview & Revenue Model
Company Description
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney ...
Grey Matters Health Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Grey Matters Health Technical Analysis
Positive
0.45
Price Trends
0.43
Positive
0.44
Positive
0.51
Positive
Market Momentum
0.04
Negative
62.13
Neutral
71.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GREY, the sentiment is Positive. The current price of 0.45 is below the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.43, and below the 200-day MA of 0.51, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 62.13 is Neutral, neither overbought nor oversold. The STOCH value of 71.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:GREY.
Grey Matters Health Peers Comparison
UnderperformOutperform
Sector (51)
TSE:GREY
Grey Matters Health
0.55
-0.15
-21.43%
TSE:APLI
Appili Therapeutics Inc Class A
0.01
>-0.01
-33.33%
TSE:RKV
Rakovina Therapeutics Inc
0.22
-0.20
-47.62%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.25
-3.76
-93.88%
TSE:NURL
Neural Therapeutics Inc.
0.02
>-0.01
-25.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.